What Hotel Markets are Currently Seeing the Most Revenue Success?

On this week’s episode of Say Yes to Travel, we got to sit down with Jonathan Capps, Vice President of Revenue, and Gavin Royster, Director of Development, at Charlestowne Hotels.

They provided some great insight regarding revenue and development strategies both in the current climate and as we move past this unprecedented period into a new normal and beyond.

Charlestowne has a large portfolio of hotels in destinations around the country. The company is an interesting case study, because the size and scope and scope of its portfolio has led to unique outcomes. In many ways, having properties that are small to medium and independent in secondary leisure markets has allowed the company to manage the changes this year well.

The varied portfolio has also brought challenges, as each destination has required different protocol changes. In essence, no property faced the same protocols or requirements due to being based in different states and markets.

But there were also a lot of lessons learned. For those properties that remained open, they were training and learning “on the fly” and make changes in real-time. The benefit for those hotels that closed and reopened was an ability to glean information and best practices from some of the other properties that remained open.

A shift in marketing was also pivotal and has felt like a rebrand around cleanliness. Clean is now everything in the world of hospitality, and all of the company’s hotels were able to shift with that as a primary focus.

We covered much more throughout the episode, including:

  • How daily responsibilities and communication/collaboration interdepartmentally and with properties in regards to revenue and markets has changed
  • Revenue strategies that hoteliers have adopted for 2020 and will need to adopt for 2021
  • Types of hotels (i.e. condo-hotels, boutique, beach) that will be most sought-after post-pandemic
  • Markets currently seeing the most revenue success
  • The future of hotel development and markets primed for “post-COVID” development

Give a listen for all the details, and for more information on Charlestowne Hotels, check out their website.

Say Yes To Travel has a new episode every Thursday!

Say Yes to Travel with Sarah Dandashy

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More